Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF

NCT00003490 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT00003490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II to Treat Multiple Myeloma Patients With Cytoxan and Vincristine After Cycling Myeloma Cells With rHuGM-CSF
Lead sponsor
The Cleveland Clinic
Phase
Phase 2
Overall status
Completed
Start date
October 31, 1998
Completion date
August 31, 2003
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma and plasma cell neoplasm